You’re over 40, and you’ve noticed something you can’t quite put your finger on. You get sick more often than you used to. A cold that would have been two days now lingers for a week. You recovered from COVID but your energy never fully came back. Or maybe you’re watching a parent deal with the slow erosion of immune function that comes with aging and wondering if there’s anything proactive you can do.
Then you heard about Thymosin Alpha-1 — an immune-modulating peptide that’s actually approved as a pharmaceutical in over 35 countries, has been studied in more than 30 clinical trials with 11,000+ human subjects, and yet somehow ended up on the FDA’s restricted list in the United States.
This is arguably the most compelling regulatory story on the entire Category 2 list. Here’s the full picture — what the evidence shows, why it’s restricted, and what it means for your options.
Thymosin Alpha-1
Tα1 (Immune Modulator)
Also known as: Thymalfasin, Zadaxin
Evidence Summary
- Strongest evidence for:
- Hepatitis B and C treatment (multiple RCTs, basis for approval in 35+ countries), vaccine response enhancement in elderly/immunocompromised patients, general immune modulation and immunosenescence
- Promising but early:
- Cancer support as adjunct to chemotherapy (improved survival in lung/liver cancer studies), sepsis (mixed results — the 2025 TESTS trial showed no mortality benefit), COVID-19 (reduced cytokine storms in retrospective studies)
- Mostly anecdotal:
- General longevity and anti-aging effects beyond measurable immune markers
- Key limitation:
- Despite extensive global approval and clinical data, U.S. regulatory status remains restricted. The safety concern is about compounding quality, not the molecule itself.
What It Is
Thymosin Alpha-1 is a 28-amino-acid peptide originally isolated from the thymus gland — the small organ behind your sternum responsible for producing and training your immune system’s T-cells. Your thymus is most active in childhood and begins shrinking starting in your twenties. By age 50, it has significantly atrophied, which is a major contributor to age-related immune decline (immunosenescence). Critically, Tα1 is an immunomodulator, not an “immune booster.” It doesn’t simply crank up immune activity (which could worsen autoimmune conditions). It restores balanced immune function: enhancing responses that are too weak while potentially calming responses that are overactive. It acts primarily on Toll-like receptors on dendritic cells, promoting T-cell maturation and optimizing the balance between different arms of your immune system. This is arguably the strongest regulatory case on the entire Category 2 list. Its synthetic form (Zadaxin) is approved in over 35 countries with 11,000+ subjects of safety data. Its placement on the Category 2 list was among the most criticized decisions by clinicians.
What the Research Says
Hepatitis B and C
T1: Strong EvidenceMultiple RCTs showing Tα1 alone or with interferon significantly improves sustained virologic response. Basis for approval in 35+ countries. Phase III trials for hepatitis C conducted in the U.S.
Vaccine Enhancement
T1: Strong EvidenceClinical studies show significantly improved influenza vaccine response in elderly and immunocompromised patients who typically mount poor responses.
Immune Modulation
T2: Emerging EvidenceExtensive evidence supporting enhanced CD4+ and CD8+ T-cell function, dendritic cell maturation, and restored immune competence. A 2024 review of 30+ trials concluded Tα1 is “a well-tolerated and effective immune modulator.”
Cancer Support
T2: Emerging EvidenceImproved overall survival in non-small-cell lung cancer and liver cancer as an adjunct. Reduced chemotherapy-induced lymphopenia. Not a cancer treatment — an immune modulator used alongside standard oncology.
Sepsis
T3: Early / AnecdotalUsed clinically in China. The 2025 TESTS trial (BMJ) found no evidence of reduced 28-day mortality. Mixed data despite clinical use — an honest assessment.
COVID-19
T3: Early / AnecdotalRetrospective studies showed reduced cytokine storms and reversed T-cell exhaustion in severe cases. Promising but not definitive.
It’s worth noting: without controlled human trials, we can’t rule out that practitioner-reported benefits are placebo, coincidental with other interventions or overstated. The mechanistic rationale is sound, but sound rationale isn’t proof.
Typical Protocol
| Route | Subcutaneous injection |
| Dosage Range | 1.6 mg (standard clinical dose based on the approved Zadaxin protocol) |
| Frequency | 2–3 times per week. Acute immune support: daily for 1–2 weeks. |
| Cycle Length | Varies by indication. Maintenance: twice weekly ongoing. |
| Time to Effect | Immune markers detectable in bloodwork within 1–2 weeks. Subjective improvements in illness susceptibility over 4–8 weeks. |
| Note | Based on the globally approved Zadaxin protocol. Provider determines your specific schedule. |
Protocols vary by individual. Always follow your prescribing provider's instructions.
Risks & Side Effects
- One of the most favorable safety profiles of any immunomodulatory agent — across 30+ trials and 11,000+ subjects, no significant adverse drug interactions observed.
- Injection site irritation — mild and the most commonly reported side effect.
- Compounding quality risk — the FDA flagged that compounded Tα1 may pose immunogenicity risk depending on manufacturing quality. This is a compounding concern, not a molecule concern. Verify pharmacy sourcing.
- Theoretical autoimmune concern — as an immune modulator, discuss with your provider if you have an autoimmune history. Clinical data has not shown worsening.
Who Should Not Consider Thymosin Alpha-1
If you have an active autoimmune condition: Tα1 is modulatory rather than purely stimulatory, and clinical data has not shown worsening of autoimmune conditions. But the theoretical concern is real, and the conversation belongs with the specialist managing your autoimmune disease, not just your peptide provider.
If you are receiving cancer treatment: Tα1 has been studied in oncology adjuvant settings and may have a role alongside standard treatment in specific cancers. But it is not a cancer therapy, and combining it with chemotherapy, radiation, or immune checkpoint inhibitors should be coordinated with your oncologist — not added independently.
If you are pregnant or breastfeeding: Despite extensive trial data in other populations, Tα1 has not been adequately studied in pregnancy or lactation. Absolute contraindication.
If your provider can’t verify their compounding pharmacy: The FDA flagged immunogenicity risk specifically tied to compounding quality. If your provider can’t name their pharmacy, confirm USP compliance, or explain their third-party testing, that is a hard stop — not because of Tα1 itself, but because immunogenic impurities in an immunomodulatory drug are exactly the wrong thing to introduce.
Legal & Access Status
FDA orphan drug designation for several conditions but not broadly FDA-approved in the United States. Category 2 since late 2023. PCAC-referred September 2024 — among the first five compounds in the formal reclassification process. Has the strongest regulatory case for reclassification given approval in 35+ countries. Included in the February 2026 announcement.
Before You Start: Get Baseline Labs
We recommend baseline lab work before starting any peptide protocol so you and your provider can track changes. Key markers include IGF-1, fasting glucose, CBC, CMP and a thyroid panel.
Ask your provider about ordering these labs, or search for direct-to-consumer lab testing services in your area.
Lab recommendations are the same regardless of which service you use. See how we make money.
What You'll Need
If your provider prescribes an injectable protocol, you'll need basic supplies.
- Bacteriostatic Water (30ml)Link coming soon
- Insulin Syringes 29 gauge (100ct)Link coming soon
- Alcohol Prep Pads (200ct)Link coming soon
- Sharps ContainerLink coming soon
Supply links are affiliate links. We may earn a commission at no cost to you. We only link to commodity supplies, never to peptide products. See how we make money.
Questions for Your Provider
- 1Based on my immune labs (CD4/CD8 counts, NK cell activity), am I a good candidate?
- 2Are you prescribing this for general immune optimization or a specific condition? What outcome are we measuring?
- 3Which compounding pharmacy are you sourcing from? Do they hold current USP compliance?
- 4What monitoring schedule and immune markers will we track?
- 5I have [autoimmune condition/cancer history] — is Tα1 appropriate?
- 6How does pricing compare between compounded Tα1 and Zadaxin sourced internationally?
Find a Provider
We’re finalizing our vetted provider list. Subscribe to be notified when provider recommendations go live.
When provider links go live, we’ll disclose all affiliate relationships here. See how we make money.
Stay ahead of the FDA.
Regulatory updates as developments happen. New compound profiles weekly. No spam. No sales pitches.